3.01
3.61%
0.105
Dopo l'orario di chiusura:
2.90
-0.11
-3.65%
Precedente Chiudi:
$2.905
Aprire:
$2.96
Volume 24 ore:
881.46K
Relative Volume:
1.10
Capitalizzazione di mercato:
$231.18M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-10.42%
1M Prestazione:
+0.67%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
ATYR | 3.01 | 231.18M | 0 | 0 | 0 | 0.00 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis - GlobeNewswire
Logos Global Management LP Adjusts Stake in aTyr Pharma Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 55.1% - MarketBeat
aTyr Pharma Stock Soars to 52-Week High of $3.69 Amidst Robust Gains - Investing.com UK
aTyr Pharma Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.20 loss in 3Q 2023) - Simply Wall St
Atyr Pharma: Q3 Earnings Snapshot - Houston Chronicle
aTyr Pharma Reports Q3 2024 Financial Results - TipRanks
aTyr Pharma Inc Reports Q3 Revenue of $0.353 Million, GAAP EPS L - GuruFocus.com
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
HC Wainwright Reaffirms “Buy” Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World
aTyr Pharma stock soars to 52-week high, hits $3.6 By Investing.com - Investing.com Canada
aTyr Pharma stock soars to 52-week high, hits $3.6 - Investing.com India
aTyr Pharma keeps stock price target with Buy rating by H.C. Wainwright - Investing.com UK
Atyr PHARMA's (ATYR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Decreases By 21.3% - MarketBeat
aTyr Pharma: The Bull Has Finally Come Out (NASDAQ:ATYR) - Seeking Alpha
High Growth Tech Stocks to Watch in October 2024 - Yahoo Finance
Piper Sandler remains bullish on aTyr Pharma, reiterates Overweight rating By Investing.com - Investing.com UK
It makes sense and dollars to buy Atyr Pharma Inc (ATYR) stock - SETE News
Financial Metrics Check: Atyr Pharma Inc (ATYR)’s Ratios for Trailing Twelve Months - The Dwinnex
Atyr Pharma Inc Inc. (ATYR) Price Performance: The Role of Supply and Demand - The InvestChronicle
Will ATyr Pharma's Efzofitimod Data In Interstitial Lung Disease Trials Make Waves In 2025? - RTTNews
aTyr Pharma stock soars to 52-week high, hits $2.52 - Investing.com India
aTyr Pharma stock soars to 52-week high, hits $2.52 By Investing.com - Investing.com Australia
Atyr Pharma Inc (ATYR) shows promising results - US Post News
Comparing Atyr PHARMA (NASDAQ:ATYR) and Scilex (NASDAQ:SCLX) - Defense World
aTyr Pharma to Present at the LD Micro Main Event XVII in October - Vulcan Advocate
Atyr Pharma Inc (ATYR) rating initates by Wells Fargo - Knox Daily
Atyr PHARMA INC (NASDAQ:ATYR) Sees Large Increase in Short Interest - MarketBeat
Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.8500 - Knox Daily
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
Analyzing Ratios: Atyr Pharma Inc (ATYR)’s Financial Story Unveiled - The Dwinnex
Atyr Pharma Inc (ATYR) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Atyr Pharma Inc (ATYR)’s stock rises to 1.94 per share - US Post News
With 64% ownership in aTyr Pharma, Inc. (NASDAQ:ATYR), institutional investors have a lot riding on the business - Simply Wall St
aTyr Pharma's efzofitimod showcased at CHEST 2024 - Investing.com
There is no way Atyr Pharma Inc (ATYR) can keep these numbers up - SETE News
aTyr Pharma's efzofitimod showcased at CHEST 2024 By Investing.com - Investing.com UK
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for - GlobeNewswire
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting - StockTitan
Atyr Pharma Inc [ATYR] Investment Guide: What You Need to Know - Knox Daily
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):